Evaluation of the Efficacy of the Composite WM Formula in Body Weight Change

Trial details

Who runs it

TCI Co., Ltd.

Trial code

NCT07097974

Record updated

13 May 2026

Original description

This study aims to evaluate the effects of the combined formula WM Formula, used as a dietary supplement, with a focus on improvements in glycemic and lipid parameters, body composition, and gut microbiota profiles.Read full original descriptionShow less

This study aims to evaluate the effects of the combined formula WM Formula, used as a dietary supplement, with a focus on improvements in glycemic and lipid parameters, body composition, and gut microbiota profiles.

Inclusion: Adults aged 18 years or older who are willing to sign the informed consent form; Body fat percentage: ≥30% for females and ≥25% for males; Non-pregnant and non-lactating women who agree to use physical contraceptive methods (e.g., condoms, intrauterine devices) throughout the study period.

Exclusion: Acute gastroenteritis within 2 weeks prior to study initiation; Known allergy to any ingredient in the investigational product; History of chronic gastrointestinal disorders, seizure disorders or epilepsy, hepatic or renal diseases, malignancies, endocrine disorders, psychiatric illnesses, alcohol or drug abuse, or other major organic diseases based on medical history; History of gastrointestinal surgery, organ transplantation, or other major surgeries; History of hypoglycemia; Use of GLP-1 receptor agonists approved in Taiwan (e.g., liraglutide, semaglutide, dulaglutide), blood glucose-regulating medications, weight loss-related drugs or functional foods, probiotics, or gastrointestinal health-related supplements or medications within 30 days prior to the start of the study; Known lactose intolerance; Chronic diarrhea; Employees or immediate family members of TCI Co., Ltd.

ClinicalTrials.gov NCT07097974